Evidence map›Paper›PMID 25210141›Full record

Trial reportThe Journal of infectious diseases2015

Heterologous immunological effects of early BCG vaccination in low-birth-weight infants in Guinea-Bissau: a randomized-controlled trial.

Kristoffer Jarlov Jensen, Nanna Larsen, Sofie Biering-Sørensen, Andreas Andersen, Helle Brander Eriksen, Ivan Monteiro, David Hougaard, Peter Aaby, Mihai G Netea, Katie L Flanagan and 1 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04362124 (Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of SARS-COV-2 Infection in Medellín, Colombia, 2020), which is not on this map. Cited by 115 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 3 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04362124 phase3withdrawnnot on this mapstarted 2020, after this paper: background citation

Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of SARS-COV-2 Infection in Medellín, Colombia, 2020

TypeinterventionalSponsorUniversidad de AntioquiaRan2020 to 2021Enrolled0ConditionsCOVID-19Armsvaccine BCG, Placebo
3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 3 syntheses or guidelines pooled it, 191 citations in OpenAlex.

  1. Pooled it
  2. Trained innate immunity.Immunologic research · 2021
    Pooled it
  3. Pooled it
  4. Trial
  5. Differential effects of BCG vaccine on immune responses induced by vi polysaccharide typhoid fever vaccination: an explorative randomized trial.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
    Trial
  6. Trial
  7. Trial
  8. Bacillus Calmette-Guérin vaccination at birth and in vitro cytokine responses to non-specific stimulation. A randomized clinical trial.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018
    Trial
  9. Early BCG-Denmark and Neonatal Mortality Among Infants Weighing <2500 g: A Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017
    Trial
  10. Nonspecific Effects of Oral Polio Vaccine on Diarrheal Burden and Etiology Among Bangladeshi Infants.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Immune System Development-Pro Tips for Paediatricians.Acta paediatrica (Oslo, Norway : 1992) · 2026
    Review
  17. Review
  18. Review
  19. Review
  20. Review

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 4 countries.

Kristoffer Jarlov JensenResearch Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, Statens Serum Institut, Copenhagen, Department of Cardiovascular and Renal Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark Projécto de Saúde Bandim, Indepth Network, codex 1004, Bissau, Guinea-Bissau.
Nanna LarsenDanish Centre for Neonatal Screening, Statens Serum Institut, Copenhagen, Denmark.
Sofie Biering-SørensenResearch Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, Statens Serum Institut, Copenhagen.
Andreas AndersenResearch Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, Statens Serum Institut, Copenhagen.
Helle Brander EriksenResearch Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, Statens Serum Institut, Copenhagen.
Ivan MonteiroProjécto de Saúde Bandim, Indepth Network, codex 1004, Bissau, Guinea-Bissau.
David HougaardDanish Centre for Neonatal Screening, Statens Serum Institut, Copenhagen, Denmark.
Peter AabyProjécto de Saúde Bandim, Indepth Network, codex 1004, Bissau, Guinea-Bissau.
Mihai G NeteaDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Katie L FlanaganDepartment of Immunology, Monash University, Melbourne, Australia.
Christine Stabell BennResearch Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, Statens Serum Institut, Copenhagen, Projécto de Saúde Bandim, Indepth Network, codex 1004, Bissau, Guinea-Bissau OPEN, University of Southern Denmark/Odense University Hospital.
Statens Serum Institut · DKBandim Health Project · GWMonash University · AURadboud University Medical Center · NL

Funding

European Research Council 243149
6 · The paper itself

Abstract

backgroundBacillus Calmette-Guérin (BCG) seems to have beneficial nonspecific effects; early BCG vaccination of low-birth-weight (LBW) newborns reduces neonatal mortality by >40% due to prevention of primarily septicemia and pneumonia.

methodsWithin a randomized trial in LBW infants in Guinea-Bissau of early BCG vs the usual postponed BCG, a subgroup was bled 4 weeks after randomization. Levels of interleukin (IL)-1β, IL-5, IL-6, IL-10, IL-17, interferon (IFN)-γ and tumor necrosis factor (TNF)-α were measured from whole-blood assays stimulated with innate agonists to Toll-like receptor (TLR)-2, -4 or -7/8, or purified protein derivative (PPD).

resultsAmong 467 infants, BCG significantly increased the in vitro cytokine responses to purified protein derivative of Mycobacterium tuberculosis (PPD), as expected. BCG was also associated with increased responses to heterologous innate stimulation, particularly of the cytokines IL-1β, IL-6, TNF-α, and IFN-γ.

conclusionFour weeks after immunization, BCG-vaccinated infants have a significantly increased production of cytokines upon heterologous challenge, particularly T helper cell type 1 polarizing and typically monocyte-derived pro-inflammatory cytokines. BCG may accelerate the development of the neonatal immune system, mediating comprehensive protection against infections and mortality.

Indexed as

VaccinationBCG VaccineCytokinesFemaleGuinea-BissauHumansInfantInfant, Low Birth WeightInfant, NewbornMaleSeasonsSex FactorsTuberculosisBCG VaccineCytokinesAfricaBCGcytokinesheterologous immunityinfantsnonspecific effects

Identifiers

PMID25210141
PMCPMC4340366
OpenAlexW2112439253

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.